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Background
A combination of busulfan (Bu) and cyclophosphamide (Cy) has been used as a standard 
myeloablative regimen for allogeneic hematopoietic stem cell transplantation (HSCT). 
Recent studies postulate that fludarabine (Flu) is a less toxic substitute for Cy.
Methods
Forty-two patients who were diagnosed with acute leukemia or myelodysplastic syn-
drome and received BuFlu (n=17) or BuCy (n=25) from August, 1999 to July, 2009 at 
Dong-A University Medical Center were retrospectively analyzed. 
Results
The median follow-up duration was 39.75 months. The BuFlu group showed a lower in-
cidence of mucositis (P=0.005), but there was no significant intergroup difference in the 
time of engraftment, nausea/vomiting, acute/chronic graft-versus-host disease, hepatic 
veno-occlusive disease, or hemorrhagic cystitis. Moreover, the 2 groups showed no sig-
nificant difference in the cumulative risk of relapse, event-free survival, or overall survival. 
Conclusion
BuFlu administration can be employed as a preparative regimen for allogeneic HSCT and 
shows efficacy and transplant-adverse effects comparable to those of BuCy. However, 
randomized prospective studies in more patients are warranted.
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INTRODUCTION
Since the early 1980s, busulfan (Bu) has been recognized 
as an effective pretransplant agent in lieu of total body irradi-
ation in the conditioning therapy for allogeneic hema-
topoietic stem cell transplantation (HSCT). Thus, both oral 
an d int rav en ous (i.v .) f orms of  Bu h av e been  used in co mbina-
tion with cyclophosphamide (Cy), and this combination has 
become a standard myeloablative regimen for allogeneic 
HSCT [1, 2]. However, these commonly used transplant prep-
arative regimens cause a spectrum of acute and chronic tox-
icities: nausea/vomiting, oral mucositis, enteritis, hepatic ve-
no-occlusive disease (HVOD), acute graft-versus-host disease 
(aGVHD), and chronic GVHD (cGVHD) [3]. Both the por-
to-hepatic metabolism of oral Bu [4] and the specific metabo-
lite of Cy [5] are highly associated with HVOD, increased 
treatment-related mortality (TRM), and morbidity. Howev-
er, i.v. Bu administration is associated with a significantly 
lower incidence of HVOD because of the predictable bio-
availability in this route of administration and the circum-
vention of the first-pass effect of oral administration [6].
Fludarabine (Flu), a purine analog, has been shown to 
be active against a variety of hematologic malignancies [7]. 
In addition, by inhibiting lymphocyte proliferation, Flu pro-
vides sufficient immunosuppression to prevent graft rejec-Korean J Hematol 2010;45:102-8.
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tion. In the light of its established characteristics and non- 
hematological toxicities, Flu has been used in nonmyelo-
ablative transplant settings [8]. Some studies have shown 
that the use of Flu in reduced-intensity conditioning regi-
mens enabled engraftment, promoted the graft-versus-leuke-
mia effect, and was well tolerated by the patients [9-11]. 
Flu has also been combined with myeloablative doses of 
Bu (BuFlu) [12-14], and this combination showed a lower 
rate of complications, successful engraftment, and efficacy 
in patients with a high risk of leukemia and in middle-aged 
patients with related and unrelated allogeneic HSCT. 
Available retrospective data comparing BuFlu with BuCy 
suggest that BuFlu is safe and at least as effective as BuCy 
for patients who have myelogenous malignancies and are 
undergoing HSCT [15, 16]. 
In this study, we have retrospectively analyzed patients 
who had acute leukemia or myelodysplastic syndrome (MDS) 
and underwent allogeneic HSCT after myeloablative con-
ditioning regimens using BuFlu. We compared the data of 
these patients with those who received the traditional BuCy 
regimen to compare their toxicity profiles, treatment out-
comes, and overall survival (OS).
MATERIALS AND METHODS
From August, 1999 to July, 2009, 42 patients who were 
diagnosed with acute leukemia or MDS underwent HLA- 
identical allogeneic HSCT at Dong-A University Medical 
Center. The findings for 15 patients who received oral BuCy 
and 10 patients who received i.v. BuCy were compared to 
those for 17 consecutive patients who were treated with 
the myeloablative BuFlu regimen. All patients were retro-
spectively analyzed by reviewing their medical records. We 
have excluded patients with chronic myeloid leukemia or 
aplastic anemia because they had better clinical outcomes 
than patients with acute leukemia or MDS after allogeneic 
HSCT.
1. Pretransplant regimen
In the BuCy group, oral Bu (Myran, Korea United Pharm., 
Chungnam, Republic of Korea, 1 mg/kg) or i.v. Bu (Busulfex, 
Ben Venue Laboratories Inc., Bedford, Ohio, USA, 0.8 mg/kg) 
was administered every 6 hours for 4 days (days -7 to -4), 
followed by i.v. Cy (60 mg/kg) for 2 days (days -3 to -2). 
The chemotherapy doses were based on the ideal body weight 
(IBW), except in the patients whose real body weight (RBW) 
exceeded their IBW by more than 20%; in such cases, the 
doses were based on an adjusted IBW, which was calculated 
as IBW + (0.25 (RBW - IBW)). 
In the BuFlu group, i.v. Flu (Fludara, BaxterOncology 
GmbH, Westfalen, Germany) was administered at a dose 
of 40 mg/m
2 over 30 min for 4 days (total, 160 mg/m
2, 
days -6 to -3) along with i.v. Bu at a dose of 130 mg/m
2 
over 3 hours for 4 days (total, 520 mg/m
2, days -6 to -3). 
2. GVHD prophylaxis and supportive care
The aGVHD prophylaxis consisted of methotrexate and 
cyclosporin A. Cyclosporin A administration was started at 
a dose of 1.5 mg/kg i.v. over 3 hours q 12 hours from days 
-1 to +14 and then changed to the oral form at a dosage 
of 4-6 mg/kg bid adjusted after therapeutic drug monitoring 
at a level of 200-400 ng/mL. Patients with unrelated donors 
in the BuFlu group received rabbit-ATG (Thymoglobulin, 
IMTIX-SANGSTAT, Lyon, France) at a dose of 2.0 mg/kg 
i.v. from days -3 to -1. Methotrexate was administered at 
doses of 15 mg/m
2 on day +1 and 10 mg/m
2 on days +3, 
+6, and +11. The last dose of methotrexate was omitted 
when mucositis (≥grade 4) or renal impairment was 
observed. Phenytoin was administered during and 1 day 
after i.v. Bu-based therapy. Allogeneic donor hematopoietic 
stem cells were infused using the standard infusion technique 
on day 0. 
Infection prophylaxis consisted of a combination of cipro-
floxacin (500 mg p.o. bid), fluconazole (100 mg/day p.o. 
qd), acyclovir (250 mg/m
2 i.v. q 8 hours), and sulfamethox-
azole-trimethoprim (960 mg p.o. 3 times a week); this pro-
phylaxis began with the initiation of conditioning. 
Ursodeoxycholic acid (100 mg p.o. tid) and heparin (100 
units/kg/day i.v. continuously) were used for HVOD prophy-
laxis, which also began with the initiation of the conditioning 
therapy. A CMV antigenemia assay was performed every 
week until day +100, every 2 weeks until 6 months, and 
every 2 or 4 weeks until 12 months after engraftment.
3. Definitions
Successful neutrophil engraftment was defined as the first 
of 2 consecutive days with an absolute neutrophil count 
≥0.5×10
9/L. Failure to engraft in the absence of malignancy 
by day +30 was considered primary engraftment failure. 
Secondary graft failure was defined as initially successful 
engraftment with documented donor-derived hematopoiesis 
followed by loss of graft function without recurrent malig-
nancy. Platelet engraftment was defined as the first of 7 
consecutive days with a platelet count ≥20×10
9/L without 
transfusion.
aGVHD was defined as described by Przepiorka et al. 
[17], and cGVHD was defined as described by the “Revised 
Seattle Criteria” [18]. HVOD was graded according to the 
criteria by McDonald et al. [19]. Toxicity was scored using 
the modified National Cancer Institute criteria (CTC 3.0). 
The event-free survival (EFS) time was defined as the time 
from transplantation to relapse or death, and the OS was 
defined as the number of days from transplantation until 
death from any cause; in contrast, non-relapse mortality 
(NRM) was defined as death from any cause other than 
disease relapse.
4. Statistical analysis
Categorical variables and continuous variables were com-
pared by Fisher’s exact test and t test, respectively. OS and 
EFS were estimated using the Kaplan-Meier product limit 
method. Cumulative incidence of relapse was estimated by Korean J Hematol 2010;45:102-8.
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Table 1. Baseline patient characteristics.
　 BuCy BuFlu P
Number 25 17
Median follow-up (months) 96.2 17.3
Age (median, range) 33 (17-48) 35 (18–56) 0.390
Sex (%)
   Male 12 (48) 10 (59) 0.491
   Female 13 (52) 7 (41)
Disease (%) 0.594
   AML (CR1) 16 (64) 10 (59)
   AML (＞CR1/relapse) 1 (4) 1 (6)
   ALL (CR1) 5 (20) 2 (12)
   ALL (＞CR1/relapse) 0 0
   MDS 3 (12) 4 (23)
ABO incompatibility 0.245
   Major ABO mismatch 2 (8) 1 (6)
   Minor ABO mismatch 3 (12) 6 (35)
   Bidirectional incompatibility 2 (8) 1 (6)
Donor type (%) 0.002
   Sibling 25 (100) 11 (65)
   Unrelated 0 (0) 6 (35)
Stem cell source (%) ＜0.001
   BM 25 (100) 3 (18)
   PB 0 14 (82)
Infused cells
   TNC (×10
8)/kg 4.35±1.31
9.96±3.5
1
0.007
   MNC (×10
8)/kg 0.89±0.50
6.76±2.8
2
0.001
   CD34+ cell (×10
6)/kg 3.04±2.23
5.30±2.9
5
0.3
Abbreviations: BuCy, busulfan-cyclophosphamide; BuFlu, busulfan-
fludarabine; AML, acute myeloid leukemia; ALL, acute lymphocytic
leukemia; MDS, myelodysplastic syndrome; CR, complete re-
mission; BM, bone marrow; PB, peripheral blood; TNC, total
nucleated cell; MNC, mononucleated cell. 
Gray’s test. The Cox proportional hazard regression model 
was employed in univariate and multivariate analyses of 
OS and EFS. Calculation of adjusted P-values was performed 
by the backward selection method. This study was essentially 
explorative in nature, and therefore, no adjustment for multi-
ple testing was applied, and P-values less than 0.05 were 
considered statistically significant. All statistical analyses 
were performed using SAS 9.1.3 and R 2.9.1 statistical 
software.
RESULTS
1. Patient characteristics
Among the 42 patients who were analyzed in this study, 
25 received BuCy and 17 received BuFlu as preparative con-
ditioning therapy. Baseline patient characteristics are listed 
in T abl e 1.  Th e  med ian  pat i ent age was 34 years (range, 
17-56 years). All recipients were matched with HLA-identi-
cal donors, among whom 6 donors (14%) were unrelated. 
Twenty-eight patients underwent bone marrow trans-
plantation (BMT). Peripheral blood stem cell transplantation 
(PBSCT) was conducted in 14 patients. The mean number 
of infused total nucleated cells (TNCs)/kg, mononucleated 
cells (MNCs)/kg, and CD34+ stem cells/kg were 6.46±3.61 
(×10
8)/kg, 3.05±3.34 (×10
8)/kg, and 3.95±2.75 (×10
6)/kg, 
respectively. The median follow-up duration was 39.75 
months (range, 2.70-127.10 months). There were no inter-
group differences in age, sex, disease types of the recipients, 
ABO incompatibility status, or number of infused CD34+ 
stem cells. However, stem cell sources (P＜0.001), donor 
types (P=0.002), and total number of infused stem cells 
(TNCs, P=0.007; MNCs, P=0.001) showed statistically sig-
nificant differences. All patients in the BuCy group received 
stem cells from sibling donors and were infused with 4.35± 
1.31 (×10
8/kg) TNCs and 0.89±0.50 (×10
8/kg) MNCs. 
However, in the BuFlu group, 6 patients received stem cells 
from unrelated donors, and the remaining 11 patients re-
ceived stem cells from sibling donors; 14 patients underwent 
PBSCT, and 3 patients received BMT. Among the 6 patients 
who underwent HSCT from unrelated donors, 3 patients 
each underwent PBSCT and BMT. Patients in the BuFlu 
group were infused with TNCs [mean, 9.96±3.51 (×10
8/kg)] 
and MNCs [mean, 6.76±2.82 (×10
8/kg)]. 
2. Engraftment
All 42 patients receiving BuCy or BuFlu showed successful 
engraftment (Table 2). No primary engraftment failure or 
secondary graft failure was observed in either group. There 
were no statistically significant intergroup differences in the 
time to neutrophil engraftment (14.0 vs. 15.0 days, P=0.968) 
or platelet engraftment (13.0 vs. 17.0 days, P=0.233) after 
transplantation.
3. Toxicity profile
  1) Hepatic veno-occlusive disease
  Four cases of HVOD were observed in the BuCy group. 
Among these, 3 patients, including 1 patient who showed 
moderate HVOD, were treated with oral Bu. In the BuFlu 
group, 1 patient experienced mild HVOD. There was no 
significant difference between the number of HVOD cases 
in the 2 groups (P=0.632).
  2) Acute and chronic GVHD
  aGVHD developed in 8 patients (32%) in the BuCy group. 
Among these, 6 patients (75%) showed grade 1 aGVHD 
and 2 patients treated with oral Bu showed grade 3 aGVHD. 
Three patients (18%) showed aGVHD in the BuFlu group. 
In this group, 2 patients showed grade 1 aGVHD and 1 
patient showed grade 2 aGVHD. There was no statistically 
significant difference between the number of cases of aGVHD 
in the 2 groups (P=0.477). There were no cases of grade 
4 aGVHD in the 2 groups.
  cGVHD developed in 5 patients (20%) in the BuCy group 
and in 7 patients (41%) in the BuFlu group. Extensive cGVHD 
developed in 2 patients in the BuFlu group, but no patient 
showed extensive disease in the BuCy group. There was 
no significant difference between the number of cases of Korean J Hematol 2010;45:102-8.
BuFlu vs. BuCy for stem cell transplantation 105
Table 2. Clinical outcomes in the BuCy and BuFlu groups.
　 BuCy BuFlu P
Number 25 17
Engraftment failure (%) 0 0
Engraftment, median days (range)
   Neutrophils 15 (10-34) 14 (11-23)0.968
   Platelets 17 (8-37) 13 (8-30) 0.233
HVOD (%) 4 (16) 1 (5.9) 0.632
   Moderate to severe 1 0
Acute GVHD (%) 8 (32) 3 (18) 0.477
   Grades 2-4 acute GVHD 2 1
Chronic GVHD (%) 5 (20) 7 (41) 0.174
   Extensive 0 2
Nausea/Vomiting 25 17
   Grades 2-4 20 (80) 10 (59) 0.174
Mucositis 25 17
   Grades 2-4 17 (68) 4 (24) 0.005
Hemorrhagic cystitis 3 (12) 3 (18) 0.672
CMV antigenemia (%) 5 (20) 4 (24) 0.537
Overt CMV infection (%) 0 (0) 2 (12) 0.158
Relapse (%) 9 (36) 4 (24) 0.391
Event (%) 9 (36) 7 (41) 0.735
Death (%) 9 (36) 6 (35) 0.963
Abbreviations: BuCy, busulfan-cyclophosphamide; BuFlu, busulfan-
fludarabine; HVOD, hepatic veno-occlusive disease; GVHD, graft-
versus-host disease; CMV, cytomegalovirus.
Table 3. Cumulative risk of relapse.
6 months 12 months 18 months 24 months
BuCy 0.20 (0.08) 0.36 (0.10) 0.36 (0.10) 0.36 (0.10)
BuFlu 0.07 (0.07) 0.21 (0.11) 0.21 (0.11) 0.30 (0.14)
Values are estimate (s.e.). 
Abbreviations: BuCy, busulfan-cyclophosphamide; BuFlu, busulfan-
fludarabine.
Fig. 1. Cumulative risk of relapse.
cGVHD in the 2 groups (P=0.174).
  3) Nausea/Vomiting/Mucositis
  All patients experienced nausea, vomiting, and mucositis. 
Twenty patients (80%) in the BuCy group and 10 (59%) 
patients in the BuFlu group showed grade 2-4 nausea/ 
vomiting. Among the 20 patients in the BuCy group, 17 
were treated with oral Bu. There was no significant difference 
between the incidence of these symptoms in the 2 groups 
(P=0.174). 
  Grade 2-4 mucositis developed in 17 patients (68%) in 
the BuCy group and in 4 patients (24%) in the BuFlu group. 
There was a significant difference between the number of 
cases showing mucositis in the 2 groups (P=0.005). 
4. Hemorrhagic cystitis
  Hemorrhagic cystitis developed in 3 patients (12%) in 
the BuCy group and in 3 patients (18%) in the BuFlu group. 
There was no significant difference between the 2 groups 
(P=0.672).
5. CMV infection
　CMV antigenemia was detected in 5 patients (20%) in 
the BuCy group and in 4 patients (24%) in the BuFlu group. 
Two patients in the BuFlu group experienced CMV pneu-
monia. There was no significant difference in the occurrence 
of CMV antigenemia between the 2 groups (P=0.537).
6. Non-relapse mortality
　Three patients (7%) died for reasons not related to relapsed 
or refractory disease. All of these patients were treated with 
the BuFlu regimen and diagnosed with MDS. One patient 
died of septic shock due to delayed hospital arrival, and 
2 patients died of CMV pneumonia. 
7. Relapse
　Among the patients who underwent allogeneic HSCT, 
13 (31%) relapsed; 9 (36%) patients were treated with BuCy 
and 4 (24%) with BuFlu. The cumulative risk of relapse 
at 12 months and 24 months after transplantation were re-
spectively 36% (s.e.=10%) and 36% (s.e.=10%) in the BuCy 
group and 21% (s.e.=11%) and 30% (s.e.=14%) in the BuFlu 
group (Table 3). No significant difference in the cumulative 
risk of relapse was observed between the 2 groups (P=0.47) 
(Fig. 1).
8. Survival
　There were no significant intergroup differences in OS 
and EFS (P=0.86 and P=0.79, respectively) (Fig. 2). In the 
BuCy group, the 3-year OS and EFS were 64% (s.e.=10%) 
and 64% (s.e.=10%), respectively. In the BuFlu group, the 
3-year OS and EFS were 58% (s.e.=13%) and 55% (s.e.= 
13%), respectively. In the univariate analysis, none of the 
variables was found to affect OS and EFS. The multivariate 
analysis showed that the TNC count was associated with 
good OS and EFS (HR=0.59; 95% CI, 0.40-0.88; P=0.009 
and HR=0.69; 95% CI, 0.50-0.96; P=0.026, respectively), 
whereas the CD34+ cell count was marginally associated 
with poor OS (HR=1.34; 95% CI, 1.01-1.78; P=0.045). The Korean J Hematol 2010;45:102-8.
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Table 4. Adjusted P-values of the groups (BuFlu vs. BuCy).
HR 95% CI P Adjusted for
OS 4.43 (0.12,167.6) 0.42 Stem cell source, donor type 
TNC, MNC, CD34+ EFS 1.22 (0.08, 19.3) 0.89
Abbreviations: BuCy, busulfan-cyclophosphamide; BuFlu, busulfan-
fludarabine; OS, overall survival; EFS, event-free survival; TNC, 
total nucleated cell; MNC, mononuclear cell.
Fig. 2. Overall survival (A) and event-free survival (B).
adjusted P-values for stem cell source, donor type, and num-
ber of infused cells are shown in Table 4.
DISCUSSION
  The combination regimen of oral and i.v. Bu and Cy has 
been widely accepted as a standard preparative conditioning 
therapy in allogeneic HSCT. However, the highly cytotoxic 
effects elicited by combining these 2 alkylating drugs increase 
the TRM and morbidity in patients who undergo this 
regimen. The cytotoxicity of Cy is putatively caused by the 
initial conversion of Cy to 4-hydroxycyclophosphamide 
(HCY), a circulating metabolite that is thought to enter the 
target cells. This conversion reaction is catalyzed by perox-
idases and cytochrome P450. Exposure to HCY is modulated 
by Bu and/or phenytoin, and individuals may show sub-
stantial variability in exposure to HCY at a given dose of 
Cy [20]. Therefore, the cytotoxicity of the BuCy conditioning 
regimen affects single or multiple organs and ranges from 
mild to severe, eventually threatening the patients’ lives. 
Moreover, oral Bu administration in combination with Cy 
has been associated with HVOD. Additionally, oral Bu ad-
ministration is associated with a hepatic first-pass extraction 
effect that can result in high local Bu concentrations in 
the portal-hepatic venous system, which may conceivably 
contribute to the development of HVOD [21].
　To alleviate the oral Bu and Cy toxicities, i.v. Bu for-
mulation and an alternative immunosuppressive agent by-
passing the hepatic metabolism, that is, replacing Cy with 
a nucleoside analog, was introduced [21]. We changed the 
conditioning regimen at our institution to decrease the tox-
icity and increase the convenience of treatment because the 
long half-life of Flu allows once-daily administration.  
　Flu performs an immunosuppressive role, thereby creating 
an environment that promotes donor stem cell engraftment. 
Moreover, Flu indirectly but synergistically enhances Bu-in-
duced cytotoxicity by interfering with the repair of radiation 
therapy (XRT)- and alkylator-induced DNA damage [7]. 
However, the superiority of the BuFlu (compared to the 
BuCy) conditioning regimen in terms of the disease relapse 
rate remains controversial because a lower incidence of tox-
icity implies lesser cytotoxic effects of the drug. 
　In our study, patients who were treated with the BuFlu 
regimen conclusively benefited from the treatment with re-
gard to their oral mucositis grade. However, 15 patients 
(60%) in the BuCy group received oral Bu, but all patients 
in the BuFlu group received i.v. Bu. This difference may 
affect the statistical significance because of the unpredictable 
and erratic bioavailability of the orally administered drug.
　Although the number of patients was too small to general-
ize the results of our study, the BuFlu group showed a ten-
dency of faster platelet engraftment and lower tendencies 
to develop HVOD, grade 2-4 aGVHD, nausea, and vomiting 
in comparison with the corresponding values for the BuCy 
group. The relatively shorter time to platelet engraftment 
in the BuFlu group could be attributed to Flu itself, which 
has less cytotoxic and similar immunosuppressive effects than 
Cy, thereby allowing more easy incorporation of the donor’s 
stem cells into the recipients’ bone marrow. However, most 
of the analyzed patients in the BuFlu group received stem 
cells from peripheral blood, which may have partially con-
tributed to the rapid engraftment. As mentioned above, 
aGVHD and HVOD primarily occur due to the tissue damage Korean J Hematol 2010;45:102-8.
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caused by cytotoxic agents used in preparative conditioning 
regimens. Flu has a less direct toxic effect on the host environ-
ment, thereby lowering TRM and morbidity. However, more 
patients in the BuFlu group experienced cGVHD. This might 
have been due to the peripheral blood stem cells, which 
comprised the most significant stem cell source in this group. 
PBSCT has a higher incidence of cGVHD because the number 
of T lymphocytes in the peripheral blood is more than that 
in the bone marrow [22]. 
　In this study, both the BuCy and BuFlu groups showed 
similar rates of CMV antigenemia. Nevertheless, the patients 
in the BuFlu group showed a higher, although not significant, 
incidence of overt CMV disease, thereby resulting in a higher 
incidence of non-relapse mortality in this group. Although 
the number of patients was too small to generalize our results, 
Flu could be more immunosuppressive than Cy when in-
corporated into a conditioning regimen with Bu, thereby 
necessitating more caution with respect to serious infections. 
　The lower cytotoxicity of Flu could imply a lower anti-
tumor effect, which might induce a higher relapse rate and 
shorter survival time. In our study, patients in both groups 
showed no difference in disease recurrence or OS, as had 
been demonstrated in several studies using BuFlu [12-14]. 
Although these results are not conclusive because of the 
small number of patients analyzed and the shorter follow-up 
duration in the BuFlu group, we concluded that Flu combined 
with Bu could be an effective conditioning regimen, in lieu 
of the BuCy regimen, with fewer adverse events. 
　In this study, we used a sequential infusion regimen of 
Flu and Bu for 4 days [12]. Various doses of Flu have been 
used in the BuFlu regimen for reduced-intensity or myeloa-
blative conditioning. Although some controversies exist, the 
doses of Flu for myeloablative conditioning range from 120 
to 250 mg/m
2 [12-14]. A higher dose of Flu results in a 
lower occurrence rate of GVHD but a longer time to engraft-
ment [12, 14, 23]. However, the optimal sequence, infusion 
timing, or doses of Bu and Flu for a myeloablative condition-
ing regimen have not been established yet.
　In conclusion, the only significant benefit of the BuFlu 
regimen was the lower incidence of oral mucositis. There 
was no significant intergroup difference in the toxicity pro-
files, including the incidence of HVOD, aGVHD, cGVHD, 
nausea/vomiting, hemorrhagic cystitis, or CMV antigenemia, 
although patients in the BuFlu group tended to show shorter 
platelet engraftment times and lower incidence of HVOD, 
aGVHD, and nausea/vomiting. We observed no significant 
difference in the EFS and OS of the 2 groups. Patients in 
the BuFlu group showed a tendency toward a higher in-
cidence of severe CMV infections. Thus, Flu combined with 
Bu could be incorporated in a myeloablative conditioning 
regimen for allogeneic HSCT with an efficacy similar to 
that of Cy combined with Bu, but more caution is needed 
because the combination of Flu and Bu can induce fatal 
infections. Nevertheless, the results of our study have limited 
reliability in establishing a general consensus. First, the num-
ber of patients was too small, and the baseline donor stem 
cell types and sources of stem cells showed significant differ-
ences between the 2 groups. Second, Flu could have different 
pharmacokinetics, consequently resulting in different effi-
cacies in various diseases. Third, and of primary concern, 
the different conditioning regimens were administered se-
quentially - oral BuCy was administered from 1999-2002, 
i.v. BuCy from 2002-2005, and BuFlu from 2005-2009, there-
by resulting in different follow-up durations and “period 
effects” between the groups. The difference in the treatment 
time can affect the therapeutic results by confounding varia-
bles unrelated to the preparative conditioning regimen. 
Fourth, a selection bias exists in our study; all patients who 
had been treated with BuCy underwent allogeneic HSCT 
with related donor bone marrow; in contrast, most patients 
in the BuFlu group received peripheral blood stem cells. 
In addition, some patients in the BuFlu group received un-
related donor stem cells. Thus, randomized prospective stud-
ies in large populations comparing the BuCy and BuFlu regi-
mens are needed.
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